Drug Profile
Ulixacaltamide - Praxis Precision Medicine
Alternative Names: PRAX-944; Z 944Latest Information Update: 25 Mar 2024
Price :
$50
*
At a glance
- Originator Zalicus
- Developer Praxis Precision Medicines; Taro Pharmaceuticals USA
- Class Analgesics; Antiepileptic drugs; Benzamides; Piperidines; Small molecules
- Mechanism of Action T type calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Essential tremor
- Phase II Epilepsy
- No development reported Pain
Most Recent Events
- 29 Feb 2024 Praxis Precision Medicines completes a phase II clinical trials in Essential tremor in Canada and USA (PO) (NCT05021991)
- 05 Jan 2024 Ulixacaltamide licensed to Tenacia Biotechnology in China, Hong Kong, Macau and Taiwan
- 02 Nov 2023 Phase-III clinical trials in Essential tremor in USA (PO) (NCT06087276)